Leslie Shaw to Follow-Up Studies
This is a "connection" page, showing publications Leslie Shaw has written about Follow-Up Studies.
Connection Strength
0.318
-
Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X, Kim EJ, Wolk DA, Bennett DA, Chen-Plotkin A, Grossman M, Hu W, Lee VM, Mackin RS, Trojanowski JQ, Wilson RS, Shaw LM. Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry. 2012 Jan 03; 2:e65.
Score: 0.065
-
Sindhi R, Webber S, Goyal R, Reyes J, Venkataramanan R, Shaw L. Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. Transplant Proc. 2002 Aug; 34(5):1960.
Score: 0.034
-
Berger M, Browndyke JN, Cooter Wright M, Nobuhara C, Reese M, Acker L, Bullock WM, Colin BJ, Devinney MJ, Moretti EW, Moul JW, Ohlendorf B, Laskowitz DT, Waligorska T, Shaw LM, Whitson HE, Cohen HJ, Mathew JP. Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers. Ann Clin Transl Neurol. 2022 02; 9(2):155-170.
Score: 0.033
-
DeNofrio D, Loh E, Kao A, Korecka M, Pickering FW, Craig KA, Shaw LM. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant. 2000 Nov; 19(11):1071-6.
Score: 0.030
-
Shaw L, Smith AJ. Dental erosion--the problem and some practical solutions. Br Dent J. 1999 Feb 13; 186(3):115-8.
Score: 0.027
-
Timmers M, Bar?o S, Van Broeck B, Tesseur I, Slemmon J, De Waepenaert K, Bogert J, Shaw LM, Engelborghs S, Moechars D, Mercken M, Van Nueten L, Tritsmans L, de Strooper B, Streffer JR. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. J Alzheimers Dis. 2017; 56(4):1437-1449.
Score: 0.023
-
Le Gall JB, Milone MC, Waxman IM, Shaw LM, Harrison L, Duffy D, van de Ven C, Militano O, Geyer MB, Morris E, Bhatia M, Satwani P, George D, Garvin JH, Bradley MB, Schwartz J, Baxter-Lowe LA, Cairo MS. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients. Bone Marrow Transplant. 2013 Jan; 48(1):19-25.
Score: 0.017
-
Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010 Sep 21; 75(12):1055-61.
Score: 0.015
-
De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010 Aug; 67(8):949-56.
Score: 0.015
-
Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR, Weiner MW, Jagust WJ. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010 Jul 20; 75(3):230-8.
Score: 0.015
-
Nettiksimmons J, Harvey D, Brewer J, Carmichael O, DeCarli C, Jack CR, Petersen R, Shaw LM, Trojanowski JQ, Weiner MW, Beckett L. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging. 2010 Aug; 31(8):1419-28.
Score: 0.015
-
Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010 Jan 19; 74(3):201-9.
Score: 0.014
-
Rhim SY, Park JH, Park YS, Lee MH, Shaw LM, Kang JS. Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. Clin Ther. 2008 Apr; 30(4):633-40.
Score: 0.013
-
Miller DD, Stratmann HG, Shaw L, Tamesis BR, Wittry MD, Younis LT, Chaitman BR. Dipyridamole technetium 99m sestamibi myocardial tomography as an independent predictor of cardiac event-free survival after acute ischemic events. J Nucl Cardiol. 1994 Jan-Feb; 1(1):72-82.
Score: 0.005